by GMFH Editing Team
Important scientific progress has been made in 2019 in our understanding of the contribution of gut microbiome in health and disease. Have a look at this “2019 Year at a glance” report and discover the year’s breakthroughs in the field.
by Andreu Prados
Genes aren’t the only culprit behind the current dramatic rise in colorectal cancer prevalence. Two new articles in Nature Medicine reveal specific microbial signatures for colorectal cancer, with potential use as candidates for developing non-invasive colorectal cancer screening.
by Andreu Prados
The induction of intestinal CD8 T cells has been involved in the efficacy of cancer immunotherapy. New work has identified 11 bacterial strains that enhance resistance to Listeria infection and improve the antitumor efficacy of checkpoint inhibitors in mice.
GMFH continue to cover the important progress made in our knowledge of the gut microbiota's impact on wellbeing and disease.
by Heather Galipeau
According to a new study gut microbiota-dependent signals are critical contributors to a pre-leukemic state in mice that lack Tet2 expression.
by Andreu Prados
A new study has found that exposure to triclosan increases colonic inflammation and colitis-associated colon tumorigenesis in mice.
by Andreu Prados
This is the first study that characterizes relationships between gut microbial communities and miRNA expression in human CRC tissues.
by Andreu Prados
A review by Dr. Christian Jobin discusses how cancer immunotherapies could be used with more precision when considering gut microbiota-mediated interactions with the immune system.
A scientific committee chaired has taken care to put together a program that covers the most relevant issues in the field today.
by Andreu Prados
A new study, led by Prof. James Versalovic from the Department of Pathology at Texas Children’s Hospital and Baylor College of Medicine in Houston, has found that histamine-producing Lactobacillus reuteri reduces inflammation and suppresses colon tumours in mice.